Subsequent testing of shortlisted compounds (PD173074, cediranib, YM201636, nelarabine, tivozanib, ponatinib and dovitinib) in a panel of osteosarcoma (OS) cell lines and a pair of well-differentiated liposarcoma (LPS) cell lines validated two receptor tyrosine kinase inhibitors (RTKIs) (ponatinib, a pan-BCR-ABL inhibitor22 and PD173074, an inhibitor of FGF and VEGF receptors23) as compounds exhibiting enhanced killing of ALT cells (Fig. 1b and Supplementary Fig. 1a–d). Here, ABL1 is linked to liposarcoma.